Qiagen plans to continue deal spree

Qiagen has bet big on the future of molecular diagnostics, and it still has plenty of powder left to fire up a string of new deals. In an interview with Bloomberg, Qiagen CFO Roland Sackers says the biotech company plans to tap its $1 billion in reserves to pay for new acquisitions in a market that has seen prices slide significantly. "Now is a good time because we have seen that prices in areas we are looking for such as molecular diagnostics and applied testing have become more attractive than 12 to 18 months ago," Sackers said. "Prices in the private sector normally take time to adjust to public levels." Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.